Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

UTHR - United Therapeutics Corp


IEX Last Trade
363.32
3.100   0.853%

Share volume: 448,117
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$360.22
3.10
0.86%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
62%
Profitability 76%
Dept financing 5%
Liquidity 70%
Performance 60%
Company vs Stock growth
vs
Performance
5 Days
4.46%
1 Month
7.71%
3 Months
34.42%
6 Months
59.96%
1 Year
59.14%
2 Year
66.03%
Key data
Stock price
$363.32
P/E Ratio 
15.13
DAY RANGE
N/A - N/A
EPS 
$21.72
52 WEEK RANGE
$208.62 - $365.98
52 WEEK CHANGE
$0.59
MARKET CAP 
16.175 B
YIELD 
N/A
SHARES OUTSTANDING 
44.491 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
BETA 
0.17
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$379,369
AVERAGE 30 VOLUME 
$489,287
Company detail
CEO: Martine Rothblatt
Region: US
Website: http://www.unither.com/
Employees: 1,007
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians

Recent news